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ABSTRACT
OBJECTIVE
To examine whether sleep traits have a causal effect 
on risk of breast cancer.
DESIGN
Mendelian randomisation study.
SETTING
UK Biobank prospective cohort study and Breast 
Cancer Association Consortium (BCAC) case-control 
genome-wide association study.
PARTICIPANTS
156 848 women in the multivariable regression and 
one sample mendelian randomisation (MR) analysis in 
UK Biobank (7784 with a breast cancer diagnosis) and 
122 977 breast cancer cases and 105 974 controls 
from BCAC in the two sample MR analysis.
EXPOSURES
Self reported chronotype (morning or evening 
preference), insomnia symptoms, and sleep duration 
in multivariable regression, and genetic variants 
robustly associated with these sleep traits.
MAIN OUTCOME MEASURE
Breast cancer diagnosis.
RESULTS
In multivariable regression analysis using UK Biobank 
data on breast cancer incidence, morning preference 
was inversely associated with breast cancer (hazard 
ratio 0.95, 95% confidence interval 0.93 to 0.98 per 
category increase), whereas there was little evidence 
for an association between sleep duration and 
insomnia symptoms. Using 341 single nucleotide 
polymorphisms (SNPs) associated with chronotype, 
91 SNPs associated with sleep duration, and 57 SNPs 
associated with insomnia symptoms, one sample MR 
analysis in UK Biobank provided some supportive 
evidence for a protective effect of morning preference 
on breast cancer risk (0.85, 0.70, 1.03 per category 
increase) but imprecise estimates for sleep duration 
and insomnia symptoms. Two sample MR using data 
from BCAC supported findings for a protective effect of 
morning preference (inverse variance weighted odds 
ratio 0.88, 95% confidence interval 0.82 to 0.93 per 
category increase) and adverse effect of increased 
sleep duration (1.19, 1.02 to 1.39 per hour increase) 
on breast cancer risk (both oestrogen receptor positive 
and oestrogen receptor negative), whereas evidence 
for insomnia symptoms was inconsistent. Results 
were largely robust to sensitivity analyses accounting 
for horizontal pleiotropy.
CONCLUSIONS
Findings showed consistent evidence for a protective 
effect of morning preference and suggestive evidence 
for an adverse effect of increased sleep duration on 
breast cancer risk.
Introduction
In 2007 the World Health Organization’s International 
Agency for Research on Cancer classified shift work 
that involves circadian disruption as being probably 
carcinogenic to humans.1 Disturbed sleep, exposure 
to light at night, and exposure to other lifestyle 
factors have been proposed as possible underlying 
mechanisms.2-4 Although much of the literature on 
breast cancer risk has focused on the potentially 
adverse effects of night shift work and exposure to 
light at night, less investigation has been done into the 
potential adverse effects of sleep disruption and traits 
such as chronotype (morning or evening preference), 
sleep duration, and insomnia.5
In a meta-analysis of 28 studies, strong evidence 
suggested a positive association between circadian 
disruption and breast cancer risk (relative risk 1.14, 
95% confidence interval 1.08 to 1.21). However, 
the association with short sleep duration (<7 hours 
a night) in seven contributing studies was much less 
conclusive (0.96, 0.86 to 1.06), and no dose-response 
association with sleep deficiency was observed.6 
WHAT IS ALREADY KNOWN ON THIS TOPIC
The World Health Organization’s International Agency for Research on Cancer 
classifies shift work involving circadian disruption as probably carcinogenic to 
humans
Much of the literature on breast cancer risk has focused on the potentially 
adverse effects of night shift work and exposure to light at night, and less into 
the potential adverse effects of traits such as chronotype (morning or evening 
preference), sleep duration, and insomnia
Genetic variants robustly associated with chronotype, sleep duration, and 
insomnia symptoms have recently been identified in large genome-wide 
association studies
WHAT THIS STUDY ADDS
This study found consistent evidence for a protective effect of morning 
preference and suggestive evidence for an adverse effect of increased sleep 
duration on breast cancer risk
The evidence for insomnia symptoms was inconclusive
These findings have potential implications for influencing sleep habits of the 
general population to improve health
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Findings from other meta-analyses have been 
conflicting, with two showing no conclusive evidence 
that sleep duration is associated with breast cancer 
risk7 8 and one showing evidence of an adverse effect 
of increased sleep duration (>7 hours a night).9 Most 
studies in the meta-analyses, however, have been 
case-control designs, vulnerable to reverse causation, 
or cohort studies with a small number of cases. Fewer 
studies have investigated associations between 
chronotype and insomnia with breast cancer risk. The 
Nurses’ Health Study cohort of 72 517 women (1834 
breast cancer cases) found no strong evidence of an 
association with chronotype,10 and a prospective study 
of 33 332 women (862 incident breast cancer cases) 
in the Nord-Trøndelag Health Study (HUNT) found 
no strong evidence of an association with individual 
insomnia symptoms, although there was evidence of 
some excess risk among participants with multiple 
insomnia problems.11 Studies have tended to rely on 
self report of sleep exposures, meaning associations 
could be biased by measurement error and by residual 
or unmeasured confounding, making causal inference 
challenging.
Mendelian randomisation (MR) uses genetic variants 
that are robustly associated with potentially modifiable 
risk factors to explore causal effects on outcomes.12-14 
This method is less susceptible to measurement error, 
confounding, and reverse causation than conventional 
multivariable regression approaches, provided certain 
assumptions are met. These are that the genetic variants 
are robustly associated with the exposure of interest, 
are not associated with confounders of the exposure-
outcome relation, and do not influence the outcome 
through pathways other than the exposure of interest. 
Genetic variants robustly associated with chronotype, 
sleep duration, and insomnia symptoms have recently 
been identified in large genome-wide association 
studies (GWAS) with sample sizes of around 50 000 
to more than one million.15-23 Findings from those 
GWAS have confirmed the role of several core circadian 
genes influencing sleep traits, and identified genetic 
variants with no previously known circadian role.24 
These genetic variants have been used in two sample 
MR and provided some evidence that longer sleep 
has a causal effect on schizophrenia risk,16 whereas 
being a “morning person” is causally associated with 
a reduced risk of schizophrenia and depression,15 and 
insomnia is causally associated with an increased 
risk of type 2 diabetes, higher body mass index (BMI), 
coronary heart disease, and several psychiatric traits.17 
23 In our study we used MR to explore the causal effect 
of sleep traits on breast cancer risk.
We used genetic variants robustly associated with 
chronotype, sleep duration, and insomnia symptoms 
identified in three recent UK Biobank GWAS15-17 to 
investigate whether these sleep traits have a causal 
effect on breast cancer risk. To do this, we performed a 
one sample MR analysis using data from UK Biobank, 
from which estimates were compared with conventional 
observational multivariable regression results in the 
same study, as well as a two sample MR analysis using 
data from the Breast Cancer Association Consortium 
(BCAC).25 Furthermore, we aimed to assess the extent 
to which findings were robust to potential pleiotropy 
and supported by genetic variants associated with 
accelerometer derived measures of chronotype (sleep 
midpoint timing of the least active five hours of the 
day), sleep duration, and sleep fragmentation (number 
of nocturnal sleep episodes).
Methods
Multivariable regression and one sample MR 
analysis
Study participants
We used data on women from the UK Biobank, 
which recruited more than 500 000 participants 
(55% women) out of 9.2 million eligible adults aged 
between 40 and 70 years in the UK who were invited 
to participate (5.5% response rate).26 The study 
protocol is available online (www.ukbiobank.ac.uk/
wp-content/uploads/2011/11/UK-Biobank-Protocol.
pdf) and more details are published elsewhere.27 At 
recruitment the participants gave informed consent 
to participate and be followed-up. Overall, 503 317 
participants consented to join the study cohort and 
visited an assessment centre. Information on sleep 
traits (chronotype, sleep duration, and insomnia 
symptoms), breast cancer status (prevalent and 
incident cases with up to nine years of follow-up), 
relevant confounding factors, and genetic variants are 
available in UK Biobank.
Sleep traits
At baseline assessment, conducted in one of 22 UK 
Biobank assessment centres between 2006 and 2010, 
participants completed a touchscreen questionnaire, 
which included questions about sociodemographic 
status, lifestyle and environment, early life and family 
history, health and medical history, and psychosocial 
factors. Participants were asked about their chronotype 
(morning or evening preference), average sleep 
duration, and insomnia symptoms.
Chronotype (morning or evening preference) was 
assessed in the question “Do you consider yourself to 
be?” with one of six possible answers: “Definitely a 
‘morning’ person,” “More a ‘morning’ than ‘evening’ 
person,” “More an ‘evening’ than a ‘morning’ person,” 
“Definitely an ‘evening’ person,” “Do not know,” 
or “Prefer not to answer.” We derived a five level 
ordinal variable for chronotype where “Definitely a 
‘morning’ person,” “More a ‘morning’ than ‘evening’ 
person,” “More an ‘evening’ than a ‘morning’ person,” 
“Definitely an ‘evening’ person,” “Do not know,” or 
“Prefer not to answer” were coded as 2, 1, −1, −2, 0, 
and missing, respectively. Sleep duration was assessed 
by asking: “About how many hours sleep do you get 
in every 24 hours? (please include naps).” The answer 
could only contain integer values. Binary variables 
for short sleep duration (<7 hours v 7-8 hours) and 
long sleep duration (>8 hours v 7-8 hours) were also 
derived. To assess insomnia symptoms, participants 
were asked: “Do you have trouble falling asleep at night 
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or do you wake up in the middle of the night?” with 
responses “Never/rarely,” “Sometimes,” “Usually,” or 
“Prefer not to answer.” Those who responded “Prefer 
not to answer” were set to missing. We derived a three 
level ordinal variable for insomnia symptoms where 
“Never/rarely,” “Sometimes,” and “Usually” were 
coded as 0, 1, and 2, respectively.
Breast cancer
Participants were followed through record linkage to 
the National Health Service central registers, which 
provide information on cancer registrations, using ICD-
9 and ICD-10 (international classification of diseases, 
ninth and 10th revisions, respectively) codes and 
cancer deaths. The endpoints in these analyses were 
first diagnosis of invasive breast cancer (ICD-10 C50, 
ICD-9 174), or breast cancer listed as the underlying 
cause of death on the death certificate for women 
who died during follow-up but were not captured by 
the cancer registers. We excluded all women with 
any other cancer diagnosis from the analysis. At the 
time of analysis, mortality data were available up to 
February 2016 and cancer registry data up to April 
2015. Prevalent cases were defined as women with a 
diagnosis of breast cancer before date of recruitment 
to the UK Biobank. Incident cases were defined as 
women with a diagnosis of breast cancer or dying from 
it during follow-up.
Confounders
We considered several factors to be potential confoun-
ders of the association between sleep traits and breast 
cancer risk: education, body mass index (BMI), alcohol 
intake, smoking, strenuous physical activity, family 
history of breast cancer, age at menarche, parity, use of 
oral contraceptives, menopause status, and hormone 
replacement therapy.
BMI was derived from weight and height measured 
when participants attended the initial assessment centre, 
whereas information on other potential confounders was 
obtained from questionnaire responses completed at 
baseline (see methods in supplementary file). Additional 
information extracted from the initial assessment 
visit included centre of initial assessment visit, age at 
recruitment derived from date of birth, and date of attending 
assessment centre. Participants who were employed were 
also asked whether their current job involved night shifts: 
never/rarely, sometimes, usually, or always.
Genetic variants
The full data release in UK Biobank contains the cohort 
of successfully genotyped people (n=488 377). A total 
of 49 979 people were genotyped using the UK BiLEVE 
genotyping chip and 438 398 using the UK Biobank 
axiom genotyping chip. Pre-imputation quality 
control, phasing, and imputation of the UK Biobank 
genetic data have been described elsewhere.28
In the MR analysis, we used a total of 341 single 
nucleotide polymorphisms (SNPs) associated with 
chronotype,15 91 SNPs associated with continuous 
sleep duration,16 and 57 SNPs associated with 
insomnia symptoms17 (see supplementary file, tables 
1-3). These genetic variants were derived from self 
report and confirmed with objective sleep assessment 
and in independent cohorts.15-17
Multivariable regression analysis
We carried out separate multivariable Cox regression 
between chronotype, insomnia symptoms, and sleep 
duration and incident breast cancer to investigate 
prospective associations between these sleep traits 
and to minimise the likelihood of reverse causality 
in observational associations. To minimise the 
role of confounding, we adjusted analyses for age, 
assessment centre, and the top 40 genetic principal 
components (obtained from principal components 
analysis (PCA) to detect and quantify the genetic 
structure of populations). A second model additionally 
adjusted for education, BMI, alcohol intake, smoking, 
strenuous physical activity, family history of breast 
cancer, age at menarche, parity, menopause status, 
use of oral contraceptives, and hormone replacement 
therapy.
One sample MR analysis
For one sample MR, the genetic variants used were 
extracted genotypes from the UK Biobank imputation 
dataset (imputed to the Haplotype Reference 
Consortium reference panel), which performed 
extensive quality control including exclusion of most 
third degree or closer relatives from a genetic kinship 
analysis, as well as those who were not classified as 
white British based on questionnaire and PCA29 (see 
methods in supplementary file). Unweighted allele 
scores were generated as the total number of sleep 
trait increasing alleles (morning preference alleles 
from chronotype) present in the genotype of each 
participant.
A two stage method was implemented to give a 
population average causal hazard ratio. The first 
stage model consisted of a regression of the sleep trait 
(chronotype, sleep duration, and insomnia symptoms) 
on the allele score and the second stage model 
consisted of a Cox regression of breast cancer status 
on the fitted values from the first stage regression, with 
adjustment for age at recruitment, assessment centre, 
40 genetic principal components, and genotyping chip 
in both stages. 
Sensitivity analyses
To check the proportional hazards assumption, we 
used Pearson correlations to test Schoenfeld residuals 
from both multivariable Cox regression and one 
sample MR Cox regression models for an association 
with follow-up time.
To assess the specificity of our findings to breast 
cancer, we performed multivariable regression and 
one sample MR analysis to assess the causal effect of 
the sleep traits on other cancer diagnoses and on all 
cause mortality.
We also performed MR analysis using only those 
genetic variants that replicated at Bonferroni 
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significance in a large independent dataset for 
chronotype15 (242 variants in 23andMe, n=240 098, 
highlighted in supplementary file, table 1) to 
evaluate the potential impact of winner’s curse (ie, 
overestimation of genetic effects in the initial study), 
which can bias causal estimates in MR analysis. Given 
the relatively small sample size of replication datasets 
for sleep duration (CHARGE Consortium, n=47 180)16 
and insomnia (HUNT, n=62 533),17 few SNPs inde-
pendently replicated at Bonferroni significance to serve 
as sufficiently strong instruments for this sensitivity 
analysis.
To test the MR assumption that genetic variants 
should not be associated with confounders of the 
exposure-outcome relation, we investigated associations 
between the allele scores and potential confounders 
in UK Biobank. We then performed one sample MR 
analysis adjusted for any potential confounders found 
to be strongly associated with the allele scores (beyond 
a Bonferroni significance threshold of P<1.39×10−3) as a 
further sensitivity analysis.
We also conducted both multivariable regression and 
one sample MR using all breast cancer cases (incident 
and prevalent) in a logistic regression analysis in UK 
Biobank, and performed sensitivity analysis removing 
participants who reported currently working night 
shifts (sometimes, usually, or always).
Two sample MR analysis
We conducted a two sample MR analysis of sleep traits 
on breast cancer risk using female specific estimates of 
the associations between the genetic instruments and 
sleep traits identified in the respective GWAS15-17 in UK 
Biobank (sample 1) (see supplementary file, tables 1-3), 
and estimates of the associations between the genetic 
instruments and breast cancer from a large scale GWAS 
of breast cancer (BCAC) (sample 2).
GWAS of chronotype (five level ordinal variable), 
sleep duration (continuous variable), and insomnia 
symptoms (three level ordinal variable) were performed 
among women of European ancestry (n=241 350 - 
245 767) in the UK Biobank. This was done using BOLT-
LMM30 linear mixed models and an additive genetic 
model adjusted for age, sex, 10 genetic principal 
components, genotyping array, and genetic correlation 
matrix, as was done previously.15-17
The GWAS of breast cancer involved 122 977 women 
with the disease (oestrogen receptor positive and 
oestrogen receptor negative combined) and 105 974 
controls of European ancestry from BCAC.25 BCAC 
summary data were based on imputation to the 1000 
Genomes Project Phase 3 reference panel. To explore 
potential heterogeneity by breast cancer subtype, we 
also investigated the causal effect of the sleep traits on 
breast cancer stratified by oestrogen receptor status, 
using genetic association data from 69 501 oestrogen 
positive and 21 468 oestrogen negative cases within 
BCAC.25
Two sample MR analyses were conducted using 
“TwoSampleMR,” an R package for such analyses,31 
which was first used to extract the SNPs being used 
to instrument the exposure (here the sleep trait of 
interest) from the outcome GWAS (here breast cancer 
in BCAC). If a SNP was unavailable in the breast cancer 
GWAS summary statistics, we identified proxy SNPs 
with a minimum linkage disequilibrium (LD) r2=0.8. 
We then performed harmonisation of the direction of 
effects between exposure and outcome associations, 
where palindromic SNPs were aligned when minor 
allele frequencies were less than 0.3, or they were 
otherwise excluded. We then used an inverse variance 
weighted method to meta-analyse the SNP specific 
Wald estimates (SNP outcome estimate divided by SNP 
exposure estimate) using random effects, to obtain an 
estimate for the causal effect of the sleep trait on breast 
cancer risk.
Sensitivity analyses
The inverse variance weighted random effects method 
will return an unbiased estimate in the absence of 
horizontal pleiotropy, or when horizontal pleiotropy 
is balanced.32 To account for directional pleiotropy, 
we compared results with three other MR methods, 
which each makes different assumptions about this: 
MR Egger,33 weighted median,34 and weighted mode,35 
and therefore a consistent effect across multiple 
methods strengthens causal evidence.
To further detect and correct obtained causal 
estimates for potential violation of the MR 
assumptions,32 we performed RadialMR36 in the two 
sample analyses to identify outliers with the most 
weight in the MR analysis and the largest contribution 
to Cochran’s Q statistic for heterogeneity, which may 
then be removed and the data reanalysed. Radial MR 
analysis was conducted using modified second order 
weights and an α level of 0.05 divided by the number 
of SNPs being used to instrument the exposure. For 
the outliers identified, we also assessed their potential 
pleiotropic role by performing a phenome-wide 
association study (PheWAS) approach37 to investigate 
the associations between the SNPs and all available 
traits in the MR-Base PheWAS database (http://
phewas.mrbase.org/).
To evaluate the potential impact of winner’s curse, we 
performed two sample MR analysis using 242 genetic 
variants that replicated at Bonferroni significance in a 
large independent dataset for chronotype15 (23andMe, 
n=240 098, highlighted in supplementary file, table 1). 
We also carried out further MR analysis using robust 
adjusted profile scores, which provide an unbiased 
causal estimate in the presence of weak instruments.38
Given potential non-linear associations between 
sleep duration and breast cancer risk,9 we also used 
data on 27 SNPs associated with short sleep (<7 hours 
v 7-8 hours) and eight SNPs associated with long sleep 
(>8 hours v 7-8 hours)16 in two sample MR analysis 
(see supplementary file, tables 4 and 5). Causal effect 
estimates (ie, odds ratios for breast cancer) were rescaled 
to be interpreted for each doubling of genetic liability 
for short or long sleep, as recommended elsewhere.39
Finally, we performed two sample MR using genetic 
variants robustly associated with accelerometer 
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derived sleep traits in UK Biobank, to be compared 
with causal estimates obtained using genetic variants 
associated with self reported traits. For this we used 
genetic variants identified in GWAS in relation to three 
accelerometer based measures: timing of the least 
active five hours (L5 timing) (6 SNPs), nocturnal sleep 
duration (11 SNPs), and number of nocturnal sleep 
episodes (21 SNPs) in up to 85 205 participants, as 
previously described40 (see supplementary file, tables 
6-8). Also see the methods section in the supplementary 
file for more details about how accelerometer sleep 
traits were derived. Effect estimates represented an 
hour earlier L5 timing (correlated positively with and 
to be compared with the self reported chronotype 
measure of increased morning preference), an hour 
increase of nocturnal sleep duration (to be compared 
with self reported sleep duration), and a unit increase 
in the number of nocturnal sleep episodes (to be 
compared with self reported insomnia symptoms).
All analyses were conducted using Stata (version 15) 
and R (version 3.4.1).
Patient and public involvement
The current research was not informed by patient 
and public involvement because it used secondary 
data. However, future research following on from 
our findings should be guided by patient and public 
opinions.
No patients were involved in setting the research 
question or the outcome measures, nor were they 
involved in developing plans for design or imple-
mentation of the study. No patients were asked to 
advise on interpretation or writing up of results. The 
results of the research will be disseminated to study 
participants on request, and to stakeholders and the 
broader public as relevant.
Results
Baseline characteristics
Of the 180 216 women in the UK Biobank who had 
been successfully genotyped and passed the genetic 
quality control, and after excluding 23 368 who had 
a diagnosis of other types of cancer, 7784/156 868 
(4.9%) had received an exclusive diagnosis of breast 
cancer. Of these, 5036/156 868 (3.2%) were defined as 
prevalent cases and 2740/156 868 (1.7%) developed 
incident breast cancer over a median follow-up of 2.98 
years.
Women with a breast cancer diagnosis (prevalent or 
incident) were more likely to be older, have a higher 
BMI, be less physically active, have had an earlier 
age at menarche, be postmenopausal, have ever used 
hormone replacement therapy, have a family history 
of breast cancer, and be nulliparous. They were less 
likely to be never smokers, work night shifts, and have 
ever used oral contraceptives (table 1) compared with 
women without a breast cancer diagnosis. No strong 
difference was found in education level between 
women with and without breast cancer, in line with 
previous findings,41 as well as no clear difference in 
relation to alcohol intake.
Multivariable analysis
In multivariable Cox regression analysis, an inverse 
association was observed between morning preference 
and risk of breast cancer, which remained similar 
in the fully adjusted model (hazard ratio 0.95, 
95% confidence interval 0.93 to 0.98 per category 
increase) but there was no clear association between 
sleep duration and insomnia symptoms with risk 
of breast cancer (table 2). The proportional hazards 
assumption held for all the multivariable Cox 
regression analyses (see supplementary file, table 
9). The inverse association with morning preference 
was not observed for other cancer diagnoses (hazard 
ratio 1.00, 95% confidence interval 0.99 to 1.02 per 
category increase) (see supplementary file, table 10), 
although it was evident in multivariable Cox regression 
analysis of all cause mortality (0.95, 0.93 to 0.97 per 
category increase) (see supplementary file, table 11). 
Associations with sleep duration and insomnia were 
also observed in relation to these other outcomes (see 
supplementary file, tables 10 and 11).
When incident and prevalent cases were combined 
and associations investigated in a logistic regression 
framework, evidence was consistent for an inverse 
association between morning preference and breast 
cancer risk (odds ratio 0.96, 95% confidence interval 
0.94 to 0.98), as well a positive association between 
both sleep duration (1.02, 1.00 to 1.05 per hour 
increase) and insomnia symptoms (1.11, 1.07 to 
1.15 per category increase) with breast cancer 
risk, potentially reflecting reverse causation (see 
supplementary file, table 12). Cox regression estimates 
were similar after excluding participants who reported 
working night shifts (see supplementary file, table 13).
One sample MR analysis
Among UK Biobank female participants, allele scores 
explained 2.3% of the variance in chronotype, 0.7% 
of the variance in sleep duration, and 0.4% of the 
variance in insomnia symptoms (table 3). Some 
evidence suggested a protective effect of morning 
preference on breast cancer risk (hazard ratio 0.85, 
95% confidence interval 0.70 to 1.03 per category 
increase) and weaker evidence for an adverse effect 
of increased sleep duration (1.06, 0.70 to 1.59 
per hour increase) and insomnia symptoms (1.37, 
0.59 to 3.20 per category increase) (table 2), albeit 
imprecisely estimated (wide confidence intervals). 
The proportional hazards assumption held for all 
the one sample MR Cox regression analyses (see 
supplementary file, table 9). The protective effect of 
morning preference was not supported by MR analysis 
for other cancer diagnoses (1.05, 0.93 to 1.17 per 
category increase) (see supplementary file, table 10) 
or all cause mortality (1.15, 0.97 to 1.35 per category 
increase) (see supplementary file, table 11), although 
evidence suggested an adverse effect of insomnia on 
risk of other cancers (1.55, 0.94 to 2.55 per category 
increase) (see supplementary file, table 10).
When using only the genetic variants that replicated 
in an independent dataset (242 variants in 23andMe) 
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for chronotype, estimates of effect on breast cancer risk 
were similar (0.89, 0.71 to 1.12 per category increase); 
although with wider confidence intervals given that 
the replicated variants explained less of the variance in 
chronotype (1.6%) (see supplementary file, table 14).
Although most of the confounding factors were 
not associated with the sleep trait allele scores in UK 
Biobank, after accounting for multiple testing the 
chronotype allele score was associated with parity 
and vigorous activity; the sleep duration allele score 
was associated with age at menarche and BMI, and 
the insomnia allele score was associated with using 
hormone replacement therapy and age at menarche 
(see supplementary file, table 15). Further sensitivity 
analysis was undertaken adjusting for these potential 
confounders in the one sample MR analysis, and effect 
estimates were consistent (see supplementary file, 
table 16).
Findings of a protective effect of morning preference 
were supported in analysis of all breast cancer cases 
(incident and prevalent) in logistic regression. 
Evidence for sleep duration and insomnia symptoms 
was weaker, although both had effect estimates in the 
positive direction (see supplementary file, table 12). 
In analyses excluding women who reported working 
night shifts, findings were also consistent with the 
main results from Cox regression (see supplementary 
file, table 13).
Two sample MR analysis
After harmonisation of the SNP effects in the two 
summary datasets (UK Biobank and BCAC), 305 
SNPs were used to instrument chronotype, 82 SNPs 
were used to instrument sleep duration, and 50 SNPs 
were used to instrument insomnia symptoms. This 
included three proxy SNPs (r2≥0.8) for chronotype 
(rs376957969 for rs111867612, rs1871516 for 
rs4550782, and rs6583802 for rs61875203). Two 
sample MR supported the findings of a protective effect 
of morning preference (inverse variance weighted odds 
ratio 0.88, 95% confidence interval 0.82 to 0.93 per 
category increase) (see supplementary file, table 17 
and figure 1) as well as an adverse effect of increased 
sleep duration (1.19, 1.02, 1.39 per hour increase) 
on breast cancer risk (see supplementary file, table 
17 and figure 2). Little evidence for a causal effect of 
insomnia symptoms was observed (0.93, 0.49, 1.76 
per category increase) (see supplementary file, table 
17 and figure 3). Figure 1 shows the inverse variance 
weighted estimates for chronotype, sleep duration, and 
insomnia symptoms from two sample MR compared 
with multivariable and one sample MR approaches 
Table 1 Baseline characteristics of women who had and had not developed breast cancer by date of censoring in UK 
Biobank. Values are numbers (percentages) unless stated otherwise
Characteristic No breast cancer diagnosis (n=149 064) Breast cancer diagnosis (n=7784)
Mean (SD) age at recruitment (years); No 56.2 (7.9); n=149 064 58.9 (7.0); n=7784
Mean (SD) body mass index; No 27.0 (5.1); n=148 617 27.2 (4.9); n=7764
Mean (SD) age at menarche; No 13.0 (1.6); n=144 845 12.8 (1.6); n=7576
Mean (SD) days/week strenuous physical activity; No 1.7 (1.8); n=141 387 1.5 (1.8); n=7325
Education:
 Degree 65 381 (44.3) 3337 (43.3)
 No degree 89 383 (55.8) 4376 (56.7)
Smoking:
 Never 90 072 (60.6) 4445 (57.4)
 Former 46 374 (31.2) 2700 (34.8)
 Current 12 131 (8.2) 604 (7.8)
Alcohol use:
 Never 6254 (4.2) 343 (4.4)
 Former 5208 (3.5) 287 (3.7)
 Current 137 465 (92.3) 7145 (91.9)
Family history of breast cancer:
 Yes 9221 (6.2) 526 (6.8)
 No 139 843 (93.8) 7258 (93.2)
Parity:
 0 27 508 (18.5) 1489 (19.1)
 ≥1 121 479 (82.5) 6290 (80.9)
Oral contraceptive use:
 Yes 123 688 (83.1) 6193 (79.7)
 No 25 117 (16.9) 1580 (20.3)
Menopause:
 Yes 89 397 (60.0) 5721 (73.6)
 No 36 272 (24.4) 787 (10.1)
 Not sure 23 277 (15.6) 1266 (16.3)
Hormone replacement therapy:
 Yes 57 038 (38.4) 3142 (40.5)
 No 91 682 (61.7) 4620 (59.5)
Shift work:
 Night 4815 (5.8) 158 (4.6)
 Other 6763 (8.1) 282 (8.2)
 None 71 790 (86.1) 3014 (87.3)
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in UK Biobank. Findings were similar when stratified 
by oestrogen receptor positive and oestrogen receptor 
negative breast cancer (see supplementary file, table 
17).
Effect estimates were broadly consistent between 
the inverse variance weighted method and the 
pleiotropy robust methods applied (MR Egger, 
weighted median, and weighted mode) in two sample 
MR (see supplementary file, table 17 and figures 
1-3). Furthermore, the MR Egger test of directional 
pleiotropy was consistent with the null for all analyses 
(see supplementary file, table 18).
Evidence for heterogeneity in causal effects for 
most of the models (see supplementary file, table 
19) could still indicate potential violations of the MR 
assumptions. We used radial plots to aid in the detection 
of outlying variants. Radial MR analysis identified six 
outliers for chronotype, three for sleep duration, and 
two for insomnia symptoms in both inverse variance 
weighted and MR Egger (see supplementary file, table 
20 and figures 4-6). The pleiotropic effect of many 
of these outliers was indicated in a PheWAS of the 
SNPs on all existing traits in the MR-Base database 
(see supplementary file, figure 7). With removal of 
outliers, inverse variance weighted and MR Egger effect 
estimates were largely unchanged (see supplementary 
file, table 21).
Effect estimates for the causal effect of chronotype 
on breast cancer risk were consistent when using the 
242 genetic variants associated with chronotype, 
which replicated at Bonferroni significance in 
23andMe,15 indicating that winner’s curse is unlikely 
to have substantially biased effect estimates (see 
supplementary file, table 22). MR robust adjusted 
profile scores, which provide unbiased estimates in the 
presence of weak instruments, provided similar causal 
estimates to the main MR analysis (see supplementary 
file, table 23).
Findings of an adverse effect of increased sleep 
duration on breast cancer risk were supported using 
genetic variants specifically associated with short and 
long sleep duration, with evidence for a protective 
effect of short sleep duration on breast cancer (inverse 
variance weighted odds ratio 0.92, 95% confidence 
interval 0.86 to 0.99 per doubling of genetic liability for 
short sleep duration) and adverse effect of long sleep 
duration (1.24, 0.96 to 1.60 per doubling of genetic 
liability for long sleep duration) (see supplementary 
file, table 24).
Finally, we performed two sample MR using genetic 
variants robustly associated with accelerometer 
derived sleep traits in UK Biobank, to be compared 
with causal estimates obtained using genetic variants 
associated with self reported traits. Supplementary 
table 25 shows the genetic correlations between these 
traits. Using genetic variants robustly associated with 
accelerometer derived sleep traits in UK Biobank, 
we found no clear evidence of association with L5 
timing measured objectively (1.04, 0.78 to 1.38 per 
hour decrease) (see supplementary file, table 26 and 
figure 8). However, an adverse effect of increased 
sleep duration was supported using estimates from 
objectively measured sleep duration (1.16, 1.02 to 
1.32 per hour increase) (see supplementary file, table 
26 and figure 9) and there was some evidence for a 
causal effect of increased fragmentation on breast 
cancer risk (1.14, 1.00 to 1.30 per sleep episode) (see 
supplementary file, table 26 and figure 10). Given the 
limited availability of SNPs being used to proxy for L5 
timing to evaluate its causal role on breast cancer, and 
given the strong association found between chronotype 
and L5 timing (see supplementary file, table 25),15 
we performed a further MR analysis using the 305 
chronotype variants with SNP exposure effect estimates 
taken from the GWAS of L5 timing, to also evaluate 
the causal effect of L5 timing (see supplementary file, 
Table 2 Multivariable and mendelian randomisation Cox regression analysis for risk of breast cancer associated with sleep traits
Sleep trait
Basic model* Fully adjusted model† Mendelian randomisation analysis‡
No (incident 
cases)
Hazard ratio  
(95% CI) P value
No (incident 
cases)
Hazard ratio  
(95% CI) P value
No (incident 
cases)
Hazard ratio 
(95% CI) P value
Chronotype (per  
category increase§)
151 421 (2732) 0.94  
(0.92 to 0.97)
<0.001 138 529 (2500) 0.95  
(0.93 to 0.98)
0.002 151 421 (2732) 0.85  
(0.70 to 1.03)
0.10
Sleep duration (per hour 
increase)
150 845 (2723) 1.01  
(0.98 to 1.05)
0.55 138 228 (2495) 1.00  
(0.96 to 1.04)
0.98 150 845 (2723) 1.06  
(0.70 to 1.59)
0.78
Insomnia symptoms  
(per category increase¶)
149 005 (2740) 1.02  
(0.97 to 1.08)
0.44 138 771 (2505) 1.02  
(0.97 to 1.08)
0.44 149 005 (2740) 1.37  
(0.59 to 3.20)
0.47
*Adjusted for age, assessment centre, and top 40 genetic principal components.
†Adjusted for age, assessment centre, top 40 genetic principal components, degree status, body mass index, alcohol intake, smoking, strenuous physical activity, family history of breast cancer, 
parity, age at menarche, menopause status, use of oral contraceptives, and hormone replacement therapy.
‡Adjusted for age, assessment centre, top 40 genetic principal components, and genotyping chip.
§From definite evening, intermediate evening, don’t know, intermediate morning, and definite morning.
¶From none, some, and frequent.
Table 3 Allele scores for sleep traits in UK Biobank
Sleep trait No (incident cases)
Mean (SD) No of 
increasing alleles
Association of allele score with sleep trait*
Coefficient (SE) P value R2 F statistic
Chronotype  
(morning preference)
151 421 (2732) 336 (11.6) 0.017 (0.0003) <0.001 0.0229 3666
Sleep duration 150 845 (2723) 90 (5.9) 0.015 (0.0004) <0.001 0.0072 1127
Insomnia symptoms 149 005 (2740) 56 (4.9) 0.012 (0.0002) <0.001 0.0041 639
*Adjusted for age, assessment centre, 40 principal components, and genotyping chip.
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table 27). This analysis revealed some evidence for an 
association with L5 timing and risk of breast cancer in 
the inverse variance weighted analysis (0.86, 0.78 to 
0.95), although this estimate was not consistent across 
the pleiotropy robust methods, which were more 
consistent with the null.
Discussion
Mendelian randomisation (MR) uses genetic variation 
to investigate causal relations between potentially 
modifiable risk factors and health outcomes. In this 
study we compared observational estimates from 
multivariable regression with those from MR analyses 
to make inferences about the likely causal effects of 
three sleep traits on breast cancer risk. 
In multivariable regression analysis using data 
on breast cancer incidence in the UK Biobank study, 
morning preference was inversely associated with 
breast cancer, whereas there was little evidence for an 
association with sleep duration and insomnia. Using 
genetic variants associated with chronotype, sleep 
duration, and insomnia symptoms, one sample MR 
analysis in UK Biobank provided some evidence for a 
protective effect of morning preference but imprecise 
estimates for sleep duration and insomnia. Findings 
for a protective effect of morning preference and 
adverse effect of increased sleep duration on breast 
cancer (both oestrogen receptor positive and oestrogen 
receptor negative) were supported by two sample 
MR using data from the Breast Cancer Association 
Consortium (BCAC), whereas there was inconsistent 
evidence for insomnia symptoms. Results were largely 
robust to sensitivity analyses accounting for horizontal 
pleiotropy.
Comparison with other studies
Previous studies have found an enrichment of circadian 
pathway genetic variants in breast cancer.25  42 
Nonetheless, these studies did not directly implicate 
modifiable sleep traits by which risk of breast cancer 
Chronotype
  Multivariable logistic regression
    Incident breast cancer (basic adjustment)
    Incident breast cancer (fully adjusted)
    Incident and prevalent breast cancer (basic adjustment)
    Incident and prevalent breast cancer (fully adjusted)
  One sample MR
    Incident breast cancer
    Incident and prevalent breast cancer (basic adjustment)
  Two sample MR
Sleep duration 
  Multivariable logistic regression
    Incident breast cancer (basic adjustment)
    Incident breast cancer (fully adjusted)
    Incident and prevalent breast cancer (basic adjustment)
    Incident and prevalent breast cancer (fully adjusted)
  One sample MR
    Incident breast cancer
    Incident and prevalent breast cancer (basic adjustment)
  Two sample MR
Insomnia
  Multivariable logistic regression
    Incident breast cancer (basic adjustment)
    Incident breast cancer (fully adjusted)
    Incident and prevalent breast cancer (basic adjustment)
    Incident and prevalent breast cancer (fully adjusted)
  One sample MR
    Incident breast cancer
    Incident and prevalent breast cancer (basic adjustment)
  Two sample MR
0.94 (0.92 to 0.97)
0.95 (0.92 to 0.98)
0.95 (0.94 to 0.97)
0.96 (0.94 to 0.98)
0.85 (0.70 to 1.03)
0.87 (0.77 to 0.97)
0.88 (0.82 to 0.93)
1.01 (0.98 to 1.05)
1.00 (0.97 to 1.04)
1.02 (1.00 to 1.04)
1.02 (1.00 to 1.04)
1.06 (0.70 to 1.60)
1.16 (0.90 to 1.48)
1.19 (1.02 to 1.39)
1.02 (0.97 to 1.08)
1.02 (0.97 to 1.09)
1.12 (1.08 to 1.16)
1.13 (1.09 to 1.17)
1.38 (0.59 to 3.25)
1.09 (0.65 to 1.84)
0.80 (0.49 to 1.31)
0.8 0.90.7 1.11.0
Exposure Odds ratio
(95% CI)
Odds ratio
(95% CI)
0.6 0.8 1.2 1.61.41.0
0.4 1.0 2.2 3.42.81.6
Fig 1 | Forest plot of multivariable and mendelian randomisation (MR) estimates for association between sleep traits 
and breast cancer risk. Odds ratios are per category increase in chronotype (from definite evening, intermediate 
evening, neither, intermediate morning, definite morning), per hour increase in sleep duration, and per category 
increase in insomnia risk (from no, some, and frequent insomnia symptoms). Odds ratios rather than hazard ratios for 
incident breast cancer are shown for multivariable and one sample MR analysis to compare estimates across methods
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could be minimised and did not attempt to separate 
the effects of the genetic variants on breast cancer 
risk through circadian disruption from pleiotropic 
pathways.
Findings of an adverse effect of evening preference 
on breast cancer risk in all analyses performed 
go some way to supporting hypotheses around 
carcinogenic light-at-night 4 and findings of increased 
risk among night shift workers who might be 
exposed to artificial light at night.1 In particular, the 
specificity of the causal effect of chronotype on breast 
cancer, which was not observed in relation to other 
cancers or all cause mortality, is consistent with the 
hormonal mechanisms implicated in the light-at-
night hypothesis. However, findings when using an 
objective measure of chronotype (the least active five 
hours (L5 timing)) did not reveal the same adverse 
effect. Although this last analysis might be limited by 
the number and strength of the genetic variants used 
to instrument L5 timing, the lack of consistency in 
estimates draws to question the mechanisms by which 
morning or evening preference (rather than actual 
activity) influences breast cancer risk. Further analysis 
using the single nucleotide polymorphisms (SNPs) 
identified in relation to chronotype as instruments 
for L5 timing were consistent with a protective effect 
of morning preference, suggesting a protective effect 
of activity as well as reported preference, but as the 
pleiotropy robust tests were not consistent, more work 
is needed to distinguish the causal effect of morning 
preference from activity—for example, with the use of 
multivariable MR methods.43
Evidence for an adverse effect of increased sleep 
duration on breast cancer risk contrasts with the 
observational findings in UK Biobank as well as much 
of the literature on circadian disruption and breast 
cancer risk,6 and unlike our findings for chronotype are 
not aligned with the light at night hypothesis. However, 
recent studies implicate longer sleep duration as a risk 
factor for breast cancer.9 Given previous reports of a 
J-shaped relation between sleep duration and breast 
cancer risk,9 as well as investigating sleep duration 
as a continuous variable, we also investigated the 
causal effects of both short and long sleep duration 
to investigate non-linear effects. In line with our main 
findings, we found evidence for a protective effect 
of short sleep duration and adverse effect of long 
sleep duration on breast cancer risk. Furthermore, 
using genetic variants associated with accelerometer 
derived nocturnal sleep duration, we found evidence 
for an adverse effect of sleep duration with a similar 
magnitude of effect.
Overall, we found inconsistent evidence about the 
causal effect of insomnia symptoms on breast cancer 
risk in multivariable and MR analyses. A previous 
study of incident breast cancer in the Nord-Trøndelag 
Health Study (HUNT) revealed no strong evidence of 
an association with individual insomnia symptoms,11 
although people with multiple insomnia problems 
were found to be at increased risk. In our analysis, 
insomnia was defined based on self report of either 
difficulty initiating sleep or waking in the night. Further 
work is therefore required to investigate individual 
symptoms of insomnia on breast cancer risk, and the 
potential cumulative effect. Interestingly, MR analysis 
provided some evidence for adverse causal effect of 
accelerometer derived number of nocturnal sleep 
episodes on breast cancer risk.
Strengths and limitations of this study
Key strengths of the study are the integration of multiple 
approaches to assess the causal effect of sleep traits 
on breast cancer, the inclusion of data from two large 
epidemiological resources—UK Biobank and BCAC—as 
well as use of data derived from both self reported and 
objectively assessed measures of sleep. Furthermore, 
for MR analysis we used the largest number of SNPs 
identified in the genome-wide association studies 
(GWAS) literature, with full summary statistics 
available to obtain strong genetic instruments for MR 
analysis and to explore potential pleiotropic pathways.
The approaches of multivariable Cox regression of 
incident cases, multivariable logistic regression of 
prevalent and incident cases, one and two sample MR, 
each have different strengths and limitations in terms 
of key sources of bias (see supplementary file, table 
28). In multivariable analysis, attempts were made to 
mitigate key sources of bias, including confounding 
and reverse causation, with the use of multivariable Cox 
regression analysis of incident cases of breast cancer 
and adjustment for several hypothesised confounders. 
Nonetheless, residual or unmeasured confounding, 
selection bias, and measurement error could also 
have distorted effect estimates. We used MR analysis 
to minimise the likelihood of bias due to measurement 
error, confounding, and reverse causation. In addition, 
we conducted a series of sensitivity analyses to assess 
the core assumptions that the genetic instruments are 
strongly associated with the exposures of interest, are 
not influenced by confounding factors, and do not 
directly influence the outcome other than through the 
exposure.
One limitation of this study related to the self 
reported measures used in multivariable regression 
analyses and used to identify genetic variants for MR 
analysis. In particular, the measure of sleep duration 
might capture time spent napping and the any insomnia 
variable is really a measure of insomnia symptoms and 
not necessarily clinical insomnia. However, both these 
measures have been validated with the use of objective 
measures from accelerometer data in the UK Biobank 
and concordance is good, particularly for the effects of 
the genetic variants identified.15-17
Another limitation relates to the selection of 
participants. Analysis in the two large epidemiological 
studies included here (UK Biobank and BCAC) 
was restricted to women of European ancestry. 
Further work is required to investigate whether 
these findings translate to women in other ancestry 
groups. Although the UK Biobank represents a large 
and well characterised epidemiological resource, 
it is not representative of the UK population owing 
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to low participation.27 As well as influencing the 
generalisability of findings, selection into the study 
can lead to biased estimates of association through 
“collider bias.”44 To minimise the influence of this, we 
also used genetic data from a large case-control study 
of breast cancer (BCAC), and we compared MR effect 
estimates across these datasets.
In all MR analyses, SNP exposure estimates were 
obtained from the UK Biobank as this has formed a 
major component of the GWAS of sleep traits conducted 
to date.15-17 20 21 23 This could lead to winner’s curse, 
when the magnitude of the effect sizes for genetic 
variants identified within a discovery sample are 
likely to be larger than in the overall population. In 
a one sample MR analysis, the impact of winner’s 
curse of the SNP exposure association can bias causal 
estimates towards the confounded observational 
estimate, whereas in two sample MR, winner’s curse 
can result in bias of the causal estimate towards the 
null. To minimise the impact of winner’s curse in 
one sample MR analysis we derived an additional 
allele score for chronotype composed of SNPs that 
replicated beyond a Bonferroni correction threshold in 
an independent study (23andMe).15 Similarly, for two 
sample MR analysis, we used SNP exposure estimates 
from this replication analysis in sensitivity analyses, 
and findings were consistent with the main analysis 
(see supplementary file, tables 14 and 22).
We were unable to apply the same approach to 
investigate the impact of winner’s curse in the sleep 
duration and insomnia analysis owing to the relatively 
small sample size of the replication datasets in those 
studies, meaning genetic associations could be 
imprecise. Although we are aware of a large GWAS 
for insomnia that was conducted using data from 
both UK Biobank and 23andMe, full summary data 
for the top SNPs in the replication  analysis are not 
freely available.23 We used unweighted allele scores 
to minimise the contribution of potential weak 
instruments in the one sample MR analysis. We also 
applied a robust adjusted profile score method in the 
two sample MR analysis, which provides unbiased 
estimates in the presence of weak instruments, and 
this revealed similar causal estimates for chronotype, 
sleep duration, and insomnia as in the main analysis.
Although associations between the allele scores 
and confounders in UK Biobank imply violation of 
the MR assumption that genetic variants should not 
be associated with confounding factors, there are 
several explanations for these findings. Previous MR 
studies have identified causal effects of sleep traits 
on reproductive traits, body mass index, and activity 
levels,15-17 23 suggesting that these factors might be 
mediators of the association between sleep traits and 
breast cancer rather than confounders. Furthermore, 
some of the genetic variants associated with chronotype 
and insomnia have been found to be adiposity related 
loci,15 16 implying potential pleiotropic pathways. 
Nonetheless, we also applied a series of pleiotropy 
robust MR methods and outlier detection to rigorously 
explore the possibility that findings of a causal effect 
of chronotype and sleep duration were not biased as a 
result of pleiotropy.
As well as attempting to mitigate key sources of bias 
for each epidemiological approach applied, we also 
assessed the consistency in estimates between the 
approaches to provide the best inference about the 
causal effect of sleep traits on breast cancer. This is 
aligned with the practice of triangulation, which aims 
to obtain more reliable answers to research questions 
through the integration of results from different 
approaches, where each approach has different sources 
of potential bias that are unrelated to each other.45 46 
We also compared estimates based on self reported 
sleep with the use of genetic variants associated with 
accelerometer derived measures of sleep,40 although 
we did not use female specific SNP estimates here given 
the smaller number of participants in UK Biobank with 
these data.
Implications of findings
Findings of a protective effect of morning preference 
on breast cancer risk add to other evidence from MR 
supporting a possible beneficial effect of morning 
preference on decreased risk of schizophrenia and 
depression.15 However, whether it is the actual 
behaviour that poses the health risk or the preference 
for morning versus evening requires further evaluation. 
Further work is also required to investigate the impact 
of circadian misalignment, which can be determined by 
genetic risk, self reported chronotype, and objectively 
measured L5 timing. In addition, suggestive evidence 
for a causal effect of increased sleep duration on breast 
cancer risk should be investigated further.
Conclusions
In this study, both multivariable regression and MR 
analysis were used to provide strong evidence for 
a causal effect of chronotype on breast cancer risk. 
Furthermore, some evidence suggested a causal effect of 
sleep duration on risk of breast cancer, although findings 
for these traits were less consistent across the different 
methods applied. However, the biological role of many 
of the genetic variants used to instrument these traits in 
MR and mechanistic pathways underlying the observed 
effects are not well understood. Previously reported 
pathways between sleep disruption and mammary 
oncogenesis include immunological, molecular, 
cellular, neuroendocrine, and metabolic processes.5 
Further work to uncover these possible mediating 
processes is required. Nonetheless, these findings have 
potential implications for influencing sleep habits of the 
general population to improve health.
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